{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T23:39:29Z","timestamp":1792021169973,"version":"4.4.0"},"reference-count":47,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1038\/ajg.2016.342","type":"journal-article","created":{"date-parts":[[2016,9,6]],"date-time":"2016-09-06T08:48:39Z","timestamp":1473151719000},"page":"1796-1805","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":114,"title":["Serum Calprotectin: A Novel Diagnostic and Prognostic Marker in Inflammatory Bowel Diseases"],"prefix":"10.14309","volume":"111","author":[{"given":"Rahul","family":"Kalla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas A","family":"Kennedy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas T","family":"Ventham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ray K","family":"Boyapati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex T","family":"Adams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine R","family":"Nimmo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micaela R","family":"Visconti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hazel","family":"Drummond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gwo-Tzer","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca J","family":"Pattenden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Satsangi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-27-20210210","doi-asserted-by":"crossref","first-page":"g6670","DOI":"10.1136\/bmj.g6670","article-title":"Crohns disease.","volume":"349","author":"Kalla","year":"2014","journal-title":"BMJ"},{"key":"R2-27-20210210","doi-asserted-by":"crossref","first-page":"f432","DOI":"10.1136\/bmj.f432","article-title":"Ulcerative colitis.","volume":"346","author":"Ford","year":"2013","journal-title":"BMJ"},{"key":"R5-27-20210210","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1053\/j.gastro.2004.01.063","article-title":"Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences.","volume":"126","author":"Loftus","year":"2004","journal-title":"Gastroenterology"},{"key":"R6-27-20210210","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1016\/j.cgh.2007.07.012","article-title":"The prevalence and geographic distribution of Crohns disease and ulcerative colitis in the United States.","volume":"5","author":"Kappelman","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R7-27-20210210","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1053\/j.gastro.2008.09.012","article-title":"Direct health care costs of Crohns disease and ulcerative colitis in US children and adults.","volume":"135","author":"Kappelman","year":"2008","journal-title":"Gastroenterology"},{"key":"R8-27-20210210","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.crohns.2013.01.010","article-title":"The burden of inflammatory bowel disease in Europe.","volume":"7","author":"Burisch","year":"2013","journal-title":"J Crohns Colitis"},{"key":"R9-27-20210210","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1053\/j.gastro.2015.07.003","article-title":"Biomarkers of inflammation in inflammatory bowel disease.","volume":"149","author":"Sands","year":"2015","journal-title":"Gastroenterology"},{"key":"R10-27-20210210","first-page":"2467","article-title":"Biomarkers of inflammatory bowel disease: from classical laboratory tools to personalized medicine.","volume":"21","author":"Viennois","year":"2015","journal-title":"Inflamm Bowel Dis"},{"key":"R12-27-20210210","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1136\/gut.2006.113431","article-title":"Faecal S100A12 as a non-invasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome.","volume":"56","author":"Kaiser","year":"2007","journal-title":"Gut"},{"key":"R13-27-20210210","doi-asserted-by":"crossref","first-page":"c3369","DOI":"10.1136\/bmj.c3369","article-title":"Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis.","volume":"341","author":"van Rheenen","year":"2010","journal-title":"BMJ"},{"key":"R14-27-20210210","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1177\/1756283X14553384","article-title":"The role and utility of faecal markers in inflammatory bowel disease.","volume":"8","author":"Lehmann","year":"2015","journal-title":"Therap Adv Gastroenterol"},{"key":"R16-27-20210210","first-page":"673","article-title":"Fecal calprotectin predicts the clinical course of acute severe ulcerative colitis.","volume":"104","author":"Ho","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"R17-27-20210210","doi-asserted-by":"crossref","first-page":"e678","DOI":"10.1016\/j.crohns.2013.06.008","article-title":"Serum calprotectin as a biomarker for Crohns disease.","volume":"7","author":"Meuwis","year":"2013","journal-title":"J Crohns Colitis"},{"key":"R18-27-20210210","first-page":"26","article-title":"The intra-individual variability of faecal calprotectin: a prospective study in patients with active ulcerative colitis.","volume":"9","author":"Lasson","year":"2014","journal-title":"J Crohns Colitis"},{"key":"R19-27-20210210","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1097\/MIB.0000000000000349","article-title":"High within-day variability of fecal calprotectin levels in patients with active ulcerative colitis: what is the best timing for stool sampling? Inflamm.","volume":"21","author":"Calafat","year":"2015","journal-title":"Bowel Dis"},{"key":"R20-27-20210210","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1164\/rccm.201407-1365LE","article-title":"Measurement of serum calprotectin in stable patients predicts exacerbation and lung function decline in cystic fibrosis.","volume":"191","author":"Reid","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"R21-27-20210210","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jcf.2010.01.005","article-title":"Sputum and serum calprotectin are useful biomarkers during CF exacerbation.","volume":"9","author":"Gray","year":"2010","journal-title":"J Cyst Fibros"},{"key":"R22-27-20210210","doi-asserted-by":"crossref","first-page":"760","DOI":"10.3899\/jrheum.140628","article-title":"Calprotectin as a biomarker for rheumatoid arthritis: a systematic review.","volume":"42","author":"Abildtrup","year":"2015","journal-title":"J Rheumatol"},{"key":"R23-27-20210210","doi-asserted-by":"crossref","first-page":"e115800","DOI":"10.1371\/journal.pone.0115800","article-title":"Identification of S100A9 as biomarker of responsiveness to the methotrexateetanercept combination in rheumatoid arthritis using a proteomic approach.","volume":"9","author":"Obry","year":"2014","journal-title":"PLoS One"},{"key":"R24-27-20210210","first-page":"109","article-title":"Serum calprotectin: review of its usefulness and validity in paediatric rheumatic diseases.","volume":"33","author":"Mariani","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"R25-27-20210210","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1136\/ard.2008.103739","article-title":"Calprotectin (a major S100 leucocyte protein) predicts 10-year radiographic progression in patients with rheumatoid arthritis.","volume":"69","author":"Hammer","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"R26-27-20210210","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1097\/MIB.0000000000000273","article-title":"Accuracies of serum and fecal S100 proteins (calprotectin and calgranulin C) to predict the response to TNF antagonists in patients with Crohns disease.","volume":"21","author":"Boschetti","year":"2015","journal-title":"Inflamm Bowel Dis"},{"key":"R27-27-20210210","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.cellimm.2013.04.004","article-title":"Serum calprotectin levels correlate with biochemical and histological markers of disease activity in TNBS colitis.","volume":"282","author":"Cury","year":"2013","journal-title":"Cell Immunol"},{"key":"R30-27-20210210","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1002\/ibd.21493","article-title":"Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris classification.","volume":"17","author":"Levine","year":"2011","journal-title":"Inflamm Bowel Dis"},{"key":"R31-27-20210210","doi-asserted-by":"crossref","first-page":"4170","DOI":"10.1172\/JCI59255","article-title":"Gene expression profiling of CD8 T cells predicts prognosis in patients with Crohn disease and ulcerative colitis.","volume":"121","author":"Lee","year":"2011","journal-title":"J Clin Invest"},{"key":"R32-27-20210210","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/1471-2105-12-77","article-title":"Hainard A et al. pROC: an open-source package for R and S to analyze and compare ROC curves.","volume":"12","author":"Robin","year":"2011","journal-title":"BMC Bioinformatics"},{"key":"R33-27-20210210","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1136\/gut.2005.082909","article-title":"The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications.","volume":"55","author":"Satsangi","year":"2006","journal-title":"Gut"},{"key":"R34-27-20210210","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1161\/ATVBAHA.111.236927","article-title":"S100A8 and S100A9 in cardiovascular biology and disease.","volume":"32","author":"Averill","year":"2012","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R35-27-20210210","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.1182\/blood-2009-07-235028","article-title":"Comparison of gene expression profiles between human and mouse monocyte subsets.","volume":"115","author":"Ingersoll","year":"2010","journal-title":"Blood"},{"key":"R36-27-20210210","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1080\/00365510510013587","article-title":"Increase in plasma calprotectin during long-distance running.","volume":"65","author":"Fagerhol","year":"2005","journal-title":"Scand J Clin Lab Invest"},{"key":"R37-27-20210210","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1080\/00365520701416709","article-title":"Serum and mucosal S100 proteins, calprotectin (S100A8S100A9) and S100A12, are elevated at diagnosis in children with inflammatory bowel disease.","volume":"42","author":"Leach","year":"2007","journal-title":"Scand J Gastroenterol"},{"key":"R38-27-20210210","doi-asserted-by":"crossref","first-page":"S210","DOI":"10.1016\/S1873-9946(14)60469-4","article-title":"P349 Serum calprotectin: a novel biomarker to predict outcome in acute severe ulcerative colitis?","volume":"8","author":"Hare","year":"2014","journal-title":"J Crohns Colitis"},{"key":"R39-27-20210210","doi-asserted-by":"crossref","first-page":"7677","DOI":"10.1073\/pnas.0502178102","article-title":"Serum protein markers for early detection of ovarian cancer.","volume":"102","author":"Mor","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"R40-27-20210210","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1074\/mcp.M500055-MCP200","article-title":"An approach to studying lung cancer-related proteins in human blood.","volume":"4","author":"Xiao","year":"2005","journal-title":"Mol Cell Proteomics"},{"key":"R41-27-20210210","first-page":"41","article-title":"Clinical utility and diagnostic accuracy of faecal calprotectin for IBD at first presentation to gastroenterology services in adults aged 16-50 years.","volume":"9","author":"Kennedy","year":"2015","journal-title":"J Crohns Colitis"},{"key":"R42-27-20210210","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1038\/ajg.2015.120","article-title":"C-reactive protein, fecal calprotectin, and stool lactoferrin for detection of endoscopic activity in symptomatic inflammatory bowel disease patients: a systematic review and meta-analysis.","volume":"110","author":"Mosli","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"R43-27-20210210","doi-asserted-by":"crossref","first-page":"528","DOI":"10.3109\/00365521.2012.660542","article-title":"Surrogate markers and clinical indices, alone or combined, as indicators for endoscopic remission in anti-TNF-treated luminal Crohns disease.","volume":"47","author":"af Bjorkesten","year":"2012","journal-title":"Scand J Gastroenterol"},{"key":"R44-27-20210210","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1002\/ibd.22917","article-title":"Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease.","volume":"18","author":"DHaens","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"R45-27-20210210","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/ajg.2009.545","article-title":"Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohns disease (SES-CD) than CRP, blood leukocytes, and the CDAI.","volume":"105","author":"Schoepfer","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"R46-27-20210210","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/j.1572-0241.2007.01556.x","article-title":"Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices.","volume":"103","author":"Langhorst","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"R47-27-20210210","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1053\/j.gastro.2005.12.019","article-title":"Predictors of crohns disease.","volume":"130","author":"Beaugerie","year":"2006","journal-title":"Gastroenterology"},{"key":"R48-27-20210210","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/00004836-198808000-00011","article-title":"The clinical significance of serum C reactive protein levels in Crohns disease. Results of a prospective longitudinal study.","volume":"10","author":"Boirivant","year":"1988","journal-title":"J Clin Gastroenterol"},{"key":"R49-27-20210210","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1111\/jgh.12967","article-title":"Prospective population-based cohort of inflammatory bowel disease in the biologics era: disease course and predictors of severity.","volume":"30","author":"Niewiadomski","year":"2015","journal-title":"J Gastroenterol Hepatol"},{"key":"R50-27-20210210","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1136\/gut.2007.146357","article-title":"C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study.","volume":"57","author":"Henriksen","year":"2008","journal-title":"Gut"},{"key":"R51-27-20210210","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1002\/ibd.21933","article-title":"High-sensitivity C-reactive protein for identification of disease phenotype, active disease, and clinical relapses in Crohns disease: a marker for patient classification?","volume":"18","author":"Sandor Kiss","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"R52-27-20210210","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1136\/gut.2004.043406","article-title":"Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohns disease.","volume":"54","author":"Costa","year":"2005","journal-title":"Gut"},{"key":"R53-27-20210210","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1097\/MIB.0000000000000296","article-title":"Serum C-reactive protein and CRP genotype in pediatric inflammatory bowel disease: influence on phenotype, natural history, and response to therapy.","volume":"21","author":"Henderson","year":"2015","journal-title":"Inflamm Bowel Dis"}],"container-title":["American Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/ajg2016342.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ajg2016342","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ajg2016342.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/www.ovid.com\/00000434-201612000-00027","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T15:13:27Z","timestamp":1786547607000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00000434-201612000-00027"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":47,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1038\/ajg.2016.342","relation":{},"ISSN":["0002-9270"],"issn-type":[{"value":"0002-9270","type":"print"}],"subject":[],"published":{"date-parts":[[2016,12]]}}}